Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 6/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518590 | 0.79 | FFAR1 (0.34) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL3518863 | 0.78 | IRAK4 (0.35) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL29520345 | 0.77 | GRM5 (0.42) | GRM5LPLLIPGIRAK4 | |
| SCHEMBL31221632 | 0.77 | GSK3A (0.39) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL13028375 | 0.77 | GRM5 (0.42) | GRM5LPLLIPGIRAK4 | |
| SCHEMBL25315214 | 0.76 | PDGFRB (0.33) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL26023725 | 0.76 | PDGFRB (0.33) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL2068803 | 0.76 | APP (0.39) | FFAR1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL25922587 | 0.76 | PDGFRB (0.30) | PDGFRBKDR | |
| SCHEMBL14884085 | 0.75 | FFAR1 (0.39) | FFAR1GSK3AGSK3BPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025226862-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025016391-A1 | THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF | 南京再明医药有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024233550-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4359082-A1 | HER2 MUTATION INHIBITORS | Array BioPharma Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| WO-2013014060-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130029949-A1 | Substituted Quinolines and Their Use As Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2513128-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | University of Basel (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2011073112-A2 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION | UNIVERSITY OF BASEL (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | GRM5 2290/4885FFAR1 1185/4885GSK3A 415/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | GRM5 4385/4885FFAR1 4604/4885GSK3A 399/4885 |
| US-20240409557-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | HPGD, ADH1A, ADH5 | GRM5 658/4885FFAR1 503/4885GSK3A 3477/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | GRM5 2106/4885FFAR1 1216/4885GSK3A 357/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | GRM5 1304/4885FFAR1 940/4885GSK3A 700/4885 |
| US-20130029949-A1 | Substituted Quinolines and Their Use As Medicaments | QARS1, RECQL, CYP3A7 | GRM5 2467/4885FFAR1 1586/4885GSK3A 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.